We further analyzed the differences in inflammatory markers across IDH status in each glioma group to assess their diagnostic value in predicting IDH mutations and wild-type gliomas (Figure 5, Figure S3, Table 4). The gene discussed is IDH1; the disease is central nervous system cancer.